{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:04:12Z","timestamp":1778789052192,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","award":["EP1933709B1"],"award-info":[{"award-number":["EP1933709B1"]}],"id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018720","name":"Advanced Accelerator Applications","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1491\/A25351"],"award-info":[{"award-number":["C1491\/A25351"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8262\/A7253"],"award-info":[{"award-number":["C8262\/A7253"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1491\/A9895"],"award-info":[{"award-number":["C1491\/A9895"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1491\/A15955"],"award-info":[{"award-number":["C1491\/A15955"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C33589\/A19727"],"award-info":[{"award-number":["C33589\/A19727"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C33589\/A28284"],"award-info":[{"award-number":["C33589\/A28284"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C46\/A3976"],"award-info":[{"award-number":["C46\/A3976"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C46\/A10588"],"award-info":[{"award-number":["C46\/A10588"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ijrobp.2021.12.160","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T02:34:14Z","timestamp":1641782054000},"page":"305-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial"],"prefix":"10.1016","volume":"113","author":[{"given":"Alison","family":"Tree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Syndikus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafar","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Panades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Rimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Scrase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Staffurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.12.160_bib0001","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","article-title":"Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial","volume":"6","author":"Denham","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0002","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: Results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0003","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014Long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0004","first-page":"CD009266","article-title":"Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer","author":"Kunath","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0005","first-page":"764","article-title":"Erratum: Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis (Ann Intern Med. 2000;132:566-577)","volume":"143","author":"Seidenfeld","year":"2005","journal-title":"Ann Intern Med"},{"issue":"3 Suppl. 1","key":"10.1016\/j.ijrobp.2021.12.160_bib0006","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-4295(02)01576-5","article-title":"Antiandrogen monotherapy: Indications and results","volume":"60","author":"Iversen","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0007","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1464-410X.2006.06275.x","article-title":"Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration","volume":"98","author":"Tyrrell","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0008","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0009","first-page":"1","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer\u00a0: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"2045","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1464-410X.2006.06013.x","article-title":"Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer","volume":"97","author":"Murthy","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0167-8140(95)90055-1","article-title":"LENT SOMA tables","volume":"35","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.radonc.2007.02.014","article-title":"The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397)","volume":"83","author":"Dearnaley","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0013","first-page":"1","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer\u00a0: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"2045","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0014","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/00005650-199807000-00007","article-title":"The UCLA prostate cancer index: Development, reliability, and validity of a health-related quality of life measure","volume":"36","author":"Litwin","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0015","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0016","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0017","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0018","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0019","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0360-3016(87)90008-3","article-title":"Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate\u2014Analysis of RTOG study 75-06","volume":"13","author":"Pilepich","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0021","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"issue":"5B","key":"10.1016\/j.ijrobp.2021.12.160_bib0022","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1111\/bju.13903","article-title":"Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk strati fi cation criteria for prostate cancer","volume":"120","author":"Zumsteg","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0023","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.clgc.2014.01.006","article-title":"Greatest percentage of involved core length and the risk of death from prostate cancer in men with highest gleason score \u2265 7","volume":"12","author":"Cheney","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2005.06.005","article-title":"Bicalutamide (\u2018Casodex\u2019) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme","volume":"76","author":"Tyrrell","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7015-10-96","article-title":"Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: A systematic review","volume":"10","author":"Kunath","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0026","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0027","first-page":"62","article-title":"Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer","volume":"38","author":"Cormie","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0028","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0029","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR Trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0030","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.09319.x","article-title":"Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: Final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years","volume":"105","author":"Iversen","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0031","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.21873\/anticanres.13850","article-title":"Radiotherapy plus GnRH analogue versus high dose bicalutamide: A case control study","volume":"39","author":"Buwenge","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0032","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clgc.2012.04.003","article-title":"Neoadjuvant hormone therapy for radical prostate radiotherapy: Bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: A single-institution matched-pair analysis","volume":"10","author":"McGivern","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0033","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/cncr.30093","article-title":"PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer","volume":"122","author":"McPartlin","year":"2016","journal-title":"Cancer"},{"issue":"5 I","key":"10.1016\/j.ijrobp.2021.12.160_bib0034","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/01.ju.0000139719.99825.54","article-title":"Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6","volume":"172","author":"Iversen","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0035","doi-asserted-by":"crossref","first-page":"e3873","DOI":"10.1097\/MD.0000000000003873","article-title":"Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies","volume":"95","author":"Scailteux","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0036","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0037","first-page":"77","article-title":"Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial","volume":"21","author":"Murray","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.12.160_bib0038","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2019.10.017","article-title":"A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer","volume":"142","author":"Murray","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621034337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621034337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:58:33Z","timestamp":1778687913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621034337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0360301621034337"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.160","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}